Validated Novel Targets for Future Drug Development
The genes that underlie neural disorders provide the key for developing new pharmaceutical interventions for neurological and psychiatric disorders by way of modifying neural circuitry.
Pharmaseed Bioservices utilizes proprietary technologies for gene-silencing properties and delivery across the BBB (blood brain barrier) into the brain. These technologies, along with our extensive experience in a variety of animal models of neurological disorders, give us a significant advantage. We exploit opportunities provided by these models for the analysis of genetic and molecular regulation of cellular processes in neural disorders, and for the rapid discovery and validation of new drugs and drug targets.
Pharmaseed’s CNS platform, which links drug targets with animal models for in vivo validation, can significantly increase the probability of discovering new classes of drugs that modify neuronal function, including neuroprotectant drugs.
For more information about translational research or about Pharmaseed's preclinical CNS models please contact us and we will be happy to assist you.
|
